

Jiexin Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2167944/publications.pdf>

Version: 2024-02-01

41
papers

8,214
citations

304743

22
h-index

289244

40
g-index

48
all docs

48
docs citations

48
times ranked

14808
citing authors

#	ARTICLE	IF	CITATIONS
1	OBIF: an omics-based interaction framework to reveal molecular drivers of synergy. <i>NAR Genomics and Bioinformatics</i> , 2022, 4, lqac028.	3.2	5
2	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 2461-2473.	7.0	9
3	Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. <i>Clinical Cancer Research</i> , 2022, , .	7.0	3
4	Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung. <i>Cancer Prevention Research</i> , 2022, 15, 423-434.	1.5	1
5	Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 90-101.	5.6	22
6	Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer. <i>European Urology Oncology</i> , 2021, 4, 117-120.	5.4	5
7	Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. <i>Scientific Reports</i> , 2021, 11, 8511.	3.3	24
8	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. <i>Cancer Discovery</i> , 2021, 11, 2506-2523.	9.4	68
9	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. <i>Nature Communications</i> , 2021, 12, 2722.	12.8	74
10	Telomere dysfunction instigates inflammation in inflammatory bowel disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	28
11	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. <i>Clinical Cancer Research</i> , 2021, 27, 5072-5083.	7.0	10
12	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. <i>Clinical Cancer Research</i> , 2021, 27, 5062-5071.	7.0	8
13	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1965-1976.	4.2	14
14	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. <i>Clinical Cancer Research</i> , 2021, 27, 5049-5061.	7.0	0
15	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. <i>Nature Communications</i> , 2021, 12, 6655.	12.8	24
16	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. <i>Clinical Cancer Research</i> , 2021, 27, 5049-5061.	7.0	6
17	Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 37-46.e7.	2.6	44
18	LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. <i>Annals of Thoracic Surgery</i> , 2020, 110, 1131-1138.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 603.	12.8	140
20	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. <i>Oncotarget</i> , 2020, 11, 600-618.	1.8	15
21	Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 911-919.e6.	0.8	21
22	The Immune Landscape of Cancer. <i>Immunity</i> , 2018, 48, 812-830.e14.	14.8	3,706
23	Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1. <i>Oncogene</i> , 2018, 37, 1279-1292.	5.9	43
24	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-small Cell Lung Carcinoma Tumors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 779-791.	1.1	53
25	Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. <i>Cancer</i> , 2018, 124, 84-94.	4.1	22
26	CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. <i>Cancer Research</i> , 2018, 78, 781-797.	0.9	37
27	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018, 7, 422-437.e7.	6.2	134
28	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
29	Strategies for identification of somatic variants using the Ion Torrent deep targeted sequencing platform. <i>BMC Bioinformatics</i> , 2018, 19, 5.	2.6	24
30	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	28.9	1,742
31	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	9.4	160
32	DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. <i>Oncotarget</i> , 2017, 8, 21994-22002.	1.8	39
33	Genomic heterogeneity of multiple synchronous lung cancer. <i>Nature Communications</i> , 2016, 7, 13200.	12.8	132
34	LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress. <i>Nature Cell Biology</i> , 2016, 18, 431-442.	10.3	239
35	Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. <i>Epigenetics</i> , 2016, 11, 184-193.	2.7	52
36	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 1520-1530.	7.0	206

#	ARTICLE	IF	CITATIONS
37	Bayesian Joint Selection of Genes and Pathways: Applications in Multiple Myeloma Genomics. <i>Cancer Informatics</i> , 2014, 13s2, CIN.S13787.	1.9	9
38	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. <i>Science</i> , 2014, 346, 256-259.	12.6	834
39	Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies. <i>Neuromuscular Disorders</i> , 2014, 24, 227-240.	0.6	36
40	Sources of variation in false discovery rate estimation include sample size, correlation, and inherent differences between groups. <i>BMC Bioinformatics</i> , 2012, 13, S1.	2.6	40
41	Extracting three-way gene interactions from microarray data. <i>Bioinformatics</i> , 2007, 23, 2903-2909.	4.1	45